Category / News / Technology
-
Aspire Biopharma, Inc. Completes Stability Study of Instaprin Test Formulation
HUMACAO, PR, June 21, 2023 – Aspire Biopharma, Inc. (“Aspire” or the “Company”), a developer of disruptive drug delivery mechanism technologies, today announced that as a material part of its Development Agreement and partnership with Glatt Air Techniques, Inc. (“Glatt”), it has successfully completed a six- month the stability and solubility study of its aspirin-based product Instaprin. Working under…
-
Aspire Biopharma, Inc. and Glatt Air Techniques, Inc. Scientists Create Test Batch of Instaprin
HUMACAO, PR, November 11 2022 – Aspire Biopharma, Inc. (“Aspire” or the “Company”), a developer of disruptive drug delivery mechanism technologies, today announced that through its Development agreement and in connection with domain expert scientists from Glatt Air Techniques, Inc. (“Glatt”), Aspire and Glatt has completed the development of a “test batch” of its aspirin based product Instaprin. Working…
-
Aspire Biopharma, Inc. Signs Pharmaceutical Development Agreement with Glatt Air Techniques, Inc.
HUMACAO, PR, July 7, 2022 – Aspire Biopharma, Inc. (“Aspire” or the “Company”), a developer of disruptive drug delivery mechanism technologies, today announced that it has entered a pharmaceutical product Development Agreement with Glatt Air Techniques, Inc. (“Glatt”). The Development Agreement solidifies our strong partnership with Glatt, a world class manufacturing firm specializing in pharmaceutical and other industries, for…
-
Aspire Biopharma, Inc. Acquires Technology Assets from Instaprin Pharmaceuticals, Inc.
HUMACAO, PR, March 28, 2022 – Aspire Biopharma, Inc. (“Aspire” or the “Company”), a developer of disruptive drug delivery mechanism technologies, today announced the acquisition of the intellectual property assets (“IP”) of Instaprin Pharmaceuticals, Inc.(“Instaprin”). The acquisition of Instaprin Pharmaceuticals’ intellectual property assets includes bringing groundbreaking drug delivery technology to the Aspire portfolio. In the transaction, Aspire acquired the…